These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 27599134)
1. Patient safety and institutional review boards in multi-institutional dose escalation or expansion trials. Jones RB Lancet Oncol; 2016 Sep; 17(9):1190-1. PubMed ID: 27599134 [No Abstract] [Full Text] [Related]
2. Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards. Knopman D; Alford E; Tate K; Long M; Khachaturian AS Alzheimers Dement; 2017 Aug; 13(8):940-946. PubMed ID: 28709585 [TBL] [Abstract][Full Text] [Related]
3. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials. Gordon VM; Sugarman J; Kass N IRB; 1998; 20(1):1-5. PubMed ID: 11655324 [No Abstract] [Full Text] [Related]
4. Departmental and institutional strategies for reducing fraud in clinical research. Sessler DI; Kurz A Anesth Analg; 2012 Aug; 115(2):474-6. PubMed ID: 22826524 [No Abstract] [Full Text] [Related]
6. Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials. Lantos JD; Wendler D; Septimus E; Wahba S; Madigan R; Bliss G Clin Trials; 2015 Oct; 12(5):485-93. PubMed ID: 26374686 [TBL] [Abstract][Full Text] [Related]
7. A central institutional review board for multi-institutional trials. Christian MC; Goldberg JL; Killen J; Abrams JS; McCabe MS; Mauer JK; Wittes RE N Engl J Med; 2002 May; 346(18):1405-8. PubMed ID: 11986418 [No Abstract] [Full Text] [Related]
8. An Institutional Review Board dilemma: responsible for safety monitoring but not in control. DeMets DL; Fost N; Powers M Clin Trials; 2006; 3(2):142-8. PubMed ID: 16773956 [TBL] [Abstract][Full Text] [Related]
9. Reducing the burden on many institutional review boards. Maloney DM Hum Res Rep; 2003 Jun; 18(6):1-2. PubMed ID: 15119341 [No Abstract] [Full Text] [Related]
10. New guidance on reviews by central institutional review boards (IRBs). Maloney DM Hum Res Rep; 2005 May; 20(5):1-2. PubMed ID: 16175714 [No Abstract] [Full Text] [Related]
11. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous. Steensma DP J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584 [No Abstract] [Full Text] [Related]
12. [Application for academic multicenter studies at German ethical review boards]. Gökbuget N; Naumann R; Onkologie; 2013; 36 Suppl 2():29-35. PubMed ID: 23549034 [TBL] [Abstract][Full Text] [Related]
13. National co-operative trials in cancer in South Africa. Smit BJ; van der Merwe AP S Afr Med J; 1992 Aug; 82(2):133-4. PubMed ID: 1509327 [No Abstract] [Full Text] [Related]
16. Institutional review boards, professionalism, and the internet. Martensen R Sci Transl Med; 2010 May; 2(30):30cm15. PubMed ID: 20445198 [TBL] [Abstract][Full Text] [Related]
17. The crisis in local institutional review boards. Siegel JE; Vaughn A; Baszczewski E Ann Intern Med; 2002 Mar; 136(5):410-1; author reply 410-1. PubMed ID: 11874318 [No Abstract] [Full Text] [Related]
18. Notes from the field: jumpstarting the IRB approval process in multicenter studies. Blustein J; Regenstein M; Siegel B; Billings J Health Serv Res; 2007 Aug; 42(4):1773-82. PubMed ID: 17610447 [TBL] [Abstract][Full Text] [Related]
19. Local vs central institutional review boards for multicenter studies. Rosé CD JAMA; 2003 Oct; 290(16):2126; author reply 2126-7. PubMed ID: 14570946 [No Abstract] [Full Text] [Related]